Mucuna Pruriens
9 benefits mapped to clinical evidence across supplements.
Dose per serving from products
165 products in our catalogue print how much Mucuna Pruriens a serving holds.
Most common: 250 mg to 500 mg, 31% of 165 products.
| Dose per serving | Products |
|---|---|
| 5 mg or less | 6 |
| 5 mg to 10 mg | 14 |
| 10 mg to 25 mg | 11 |
| 25 mg to 50 mg | 17 |
| 50 mg to 100 mg | 37 |
| 100 mg to 250 mg | 23 |
| 250 mg to 500 mg | 51 |
| over 500 mg | 6 |
Benefit Evidence
Research sources
Endurance (1)
- Mucuna pruriens in untreated Parkinson's disease in sub-Saharan Africa: A 12-month, multicenter, randomized, controlled trial
PubMed ID: 41269916
12‑month clinical improvements comparable to levodopa suggest maintained functional stamina for many patients.
Energy & Fatigue (1)
- Mucuna pruriens in untreated Parkinson's disease in sub-Saharan Africa: A 12-month, multicenter, randomized, controlled trial
PubMed ID: 41269916
Sustained motor/QoL improvements over 12 months indicate probable increases in everyday energy for many patients.
Focus & concentration (1)
- Mucuna pruriens in untreated Parkinson's disease in sub-Saharan Africa: A 12-month, multicenter, randomized, controlled trial
PubMed ID: 41269916
12‑month trial showed QoL and symptom improvements vs levodopa+DDCI—longer treatment and QoL data make indirect focus benefits more plausible.
Joint mobility (1)
- Mucuna pruriens in untreated Parkinson's disease in sub-Saharan Africa: A 12-month, multicenter, randomized, controlled trial
PubMed ID: 41269916
12‑month randomized trial in untreated PD showed noninferior motor and QoL benefits vs levodopa+DDCI, supporting sustained physical ease for many.
Mental clarity (1)
- Mucuna pruriens in untreated Parkinson's disease in sub-Saharan Africa: A 12-month, multicenter, randomized, controlled trial
PubMed ID: 41269916
Longer trial with QoL improvements supports a modest chance of improved mental clarity as part of overall benefit.
Mood balance (1)
- Mucuna pruriens in untreated Parkinson's disease in sub-Saharan Africa: A 12-month, multicenter, randomized, controlled trial
PubMed ID: 41269916
12‑month randomized trial reported QoL improvements vs baseline comparable to levodopa+DDCI—supports likely mood benefit for many patients.
Motivation & confidence (1)
- Mucuna pruriens in untreated Parkinson's disease in sub-Saharan Africa: A 12-month, multicenter, randomized, controlled trial
PubMed ID: 41269916
12‑month trial showing QoL and motor improvements supports likely improved confidence for many patients.
Vitality (1)
- Mucuna pruriens in untreated Parkinson's disease in sub-Saharan Africa: A 12-month, multicenter, randomized, controlled trial
PubMed ID: 41269916
12‑month improvements in motor function and QoL indicate likely enhanced vitality for many participants.
Wellbeing (1)
- Mucuna pruriens in untreated Parkinson's disease in sub-Saharan Africa: A 12-month, multicenter, randomized, controlled trial
PubMed ID: 41269916
12‑month trial demonstrating noninferior motor and QoL improvements vs standard therapy provides the strongest evidence for sustained well‑being boost in many patients.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Mucuna Pruriens
Search all245 products whose verified label declares Mucuna Pruriens — not every bottle that mentions it in a title.